If you are reading this shortly after a diagnosis — your own, or someone you love — the most useful thing to know up front is this: the hospital ranked number one is not automatically the right hospital for you.
U.S. News Best Hospitals for Cancer, 2026-2027
The current top ten in the United States:
- The University of Texas MD Anderson Cancer Center, Houston — score 99.3/100
- Memorial Sloan Kettering Cancer Center, New York City — 88.7
- Dana-Farber Brigham Cancer Center, Boston — 84.8
- Mayo Clinic, Rochester, Minnesota
- Massachusetts General Hospital, Boston
- Johns Hopkins Hospital, Baltimore
- Hospital of the University of Pennsylvania, Philadelphia
- Northwestern Memorial Hospital, Chicago
- Stanford Health Care–Stanford Hospital, Palo Alto
- (tie) Mount Sinai Hospital, New York City, and UCSF Health–UCSF Medical Center, San Francisco — both 77.8
Rankings measure institutional performance across all cancers. You have one cancer. A center ranked twelfth nationally may treat your specific diagnosis more often, with better results, than the center ranked first. Travel, insurance networks, and how quickly you can be seen matter enormously and appear in no ranking at all.
This guide covers what the major rankings actually measure, who currently sits at the top of each, and — more importantly — the criteria oncologists themselves point to when patients ask where to go.
A Note on Sources
Everything below comes from named, published rankings and federal designations, with the methodology stated so you can judge its relevance yourself. No survival statistics have been estimated, and no outcome claims have been made that the source data does not support.
Two rankings dominate this field, and they use fundamentally different methods:
- U.S. News & World Report Best Hospitals — now in its 37th year. The 2026-2027 edition was published August 4, 2026. It evaluated approximately 4,494 hospitals using more than 800 million patient care records, and this year increased the statistical weight given to risk-adjusted patient outcomes including survival and complication rates.
- Newsweek / Statista World’s Best Specialized Hospitals — a global ranking. The 2026 oncology list draws 85% of its score from an international survey of medical professionals conducted May through July 2025, 10% from accreditations, and 5% from patient-reported outcome measures.
That difference matters. U.S. News is weighted heavily toward measured clinical outcomes. Newsweek is weighted heavily toward peer reputation. Neither is wrong; they answer different questions. A center can rank differently on each, and several do.
MD Anderson has held the top position for twelve consecutive years and has been one of the top two cancer hospitals in the country in every edition since the survey began in 1990. It runs what is described as the world’s largest cancer clinical trials program; roughly 187,000 people received treatment there in 2024, supported by approximately $1.3 billion in institutional research investment.
The gap between first and second place is worth noticing. MD Anderson’s 99.3 against Memorial Sloan Kettering’s 88.7 is a substantial margin under this methodology — but scores compress quickly after that, and by the bottom of the top ten the differences are small enough that other factors should dominate your decision.
Rankings move more than people assume
There were 51 ranking changes between the 2025-26 and 2026-27 editions. Twelve hospitals moved up, twenty-one moved down, nine dropped off the list entirely, and nine appeared for the first time.
Notable movements this year included Siteman Cancer Center at Barnes-Jewish in St. Louis rising from 27 to 21, the University of Pennsylvania climbing from 10 to 7, and UF Health Shands moving from 39 to 35. Moving the other direction, Mount Sinai fell from 6 to 10, Montefiore Einstein from 26 to 31, and the University of Michigan’s Rogel Cancer Center from 32 to 38.
This is the strongest argument against treating any ranking as gospel. A hospital does not become meaningfully worse at treating cancer in twelve months. What changes is methodology weighting, patient mix, and reporting. Use rankings to build a shortlist, not to make a final decision.
The new regional rankings may matter more than the national list
For the first time, U.S. News published regional cancer rankings alongside the national list, covering metro areas across the country. This addresses something the national top-50 never could: most patients receive care close to home, and should.
Nationally, 505 hospitals were recognized as Best Regional Hospitals across 49 states and Washington, D.C., with an additional 73 recognized for Community Access — serving underserved populations. Hospitals ranked 51 to 100 in cancer receive a “High Performing” designation.
If you cannot relocate for treatment — and most people cannot — the regional list is the more practical starting point.
The Global Picture: Newsweek World’s Best Specialized Hospitals 2026
Because this ranking surveys physicians worldwide rather than measuring American claims data, it produces a different order.
Memorial Sloan Kettering ranked first globally in oncology, with MD Anderson second — a reversal of both the previous year’s Newsweek list and the current U.S. News order. Samsung Medical Center in Seoul placed third. Johns Hopkins entered the global top ten after ranking thirteenth the previous year, and Mayo Clinic moved up one position.
Four American centers placed in the global oncology top ten, up from three the year before. The list ranks 300 hospitals for oncology in total, reflecting how many institutions worldwide now operate at a high level.
MSK’s case rests substantially on research translation: clinical trials conducted there have contributed to FDA approval of eleven new cancer drugs, and its nursing staff has earned Magnet Recognition — the highest national nursing designation — three times.
For broader context, Newsweek’s separate World’s Best Hospitals 2026 general ranking placed Mayo Clinic Rochester first, followed by Toronto General–University Health Network, Cleveland Clinic, Karolinska University Hospital in Stockholm, and Massachusetts General Hospital. That list excludes specialized hospitals, which is why MD Anderson and MSK do not appear on it.
Leading centers outside the United States
Excellent cancer care is not confined to America, and for patients outside the US the relevant question is usually which strong center is reachable, not which is theoretically best.
Institutions consistently recognized in the global oncology rankings include Samsung Medical Center and Asan Medical Center in Seoul, Princess Margaret Cancer Centre in Toronto — one of the largest cancer research hubs globally, with particular strength in radiation oncology and cancer genomics — the National Cancer Center Hospital in Tokyo, Charité in Berlin, Karolinska in Stockholm, and Gustave Roussy in Paris.
One caution about international treatment: cross-border care coordination is genuinely difficult. Continuity of records, follow-up scanning, and management of complications after you return home are the parts that go wrong. If you are considering treatment abroad, resolve those questions before you book anything.
Why NCI Designation May Matter More Than Any Ranking
For patients in the United States, this is arguably the single most useful filter, and it appears in almost no popular article on the subject.
The National Cancer Institute designates cancer centers that meet rigorous federal standards for research and care. As of 2026 there are 74 NCI-Designated Cancer Centers across 37 states and Washington, D.C. They fall into three categories:
- 58 Comprehensive Cancer Centers — the highest tier, requiring demonstrated depth in laboratory, clinical, and population-based research, plus transdisciplinary work bridging all three and substantial community outreach
- 8 Clinical Cancer Centers
- 8 Basic Laboratory Cancer Centers, primarily research-focused
Designation places a center in roughly the top 4% of the approximately 1,500 cancer centers in the United States. To even apply, an institution must receive at least $10 million annually in cancer research funding. Designation must be renewed every five years through an exhaustive review — MD Anderson’s most recent application took 24 months to prepare and ran to 2,963 pages.
Two things make this designation practically valuable:
Clinical trial access. More than 411,000 patients were newly registered at NCI-designated clinical and comprehensive centers in a recent twelve-month reporting period. If your cancer is advanced, rare, or has stopped responding to standard treatment, trial access can be the entire question.
Outcome evidence. A 2015 study of adults with newly diagnosed cancer found that patients treated at Comprehensive Cancer Centers had better outcomes than those treated at centers without the designation.
Unlike magazine rankings, NCI designation is a federal determination based on stated criteria, and the full current list is published at cancer.gov. If you check one thing, check whether a center on your shortlist holds this designation.
What Actually Determines Your Outcome
Oncologists asked where to send a family member tend to cite factors that no ranking captures well.
Volume in your specific cancer
For surgical cancers especially, the number of times a surgical team has performed your specific procedure correlates with outcomes more reliably than any institutional score. A center ranked outside the top twenty overall may be among the highest-volume programs in the country for pancreatic, esophageal, or ovarian cancer.
Ask directly: how many of these operations does this surgeon perform per year, and how many does this hospital perform?
A functioning multidisciplinary tumor board
At the strongest centers, your case is reviewed collectively by medical oncology, surgical oncology, radiation oncology, radiology, and pathology before a plan is set. This is not a formality. It is where treatment sequencing gets decided, and sequencing frequently determines what options remain available later.
Ask whether your case will be presented to a tumor board, and whether you can receive the summary.
Pathology review
Diagnostic revision at high-volume academic centers is more common than most patients expect, and a changed diagnosis changes treatment entirely. Having your slides re-read by a subspecialty pathologist at a major center is one of the highest-value, lowest-cost steps available to you.
Clinical trial availability
Ask what trials are open for your specific diagnosis and stage, and whether the center will refer you elsewhere if a better-matched trial exists. A center willing to refer you away is demonstrating something meaningful.
Insurance network status
This is the factor that most often overrides everything else. Many top-ranked centers are out-of-network for a substantial share of plans, and cancer treatment spans months. Confirm coverage — in writing, for the specific facility and physicians — before committing.
Practical Steps After a Diagnosis
Get a second opinion. It is standard practice, not an insult to your first physician. Most insurers cover it. Many major centers offer remote second-opinion services requiring only records and pathology slides.
Do not rush the first week. With rare exceptions — certain acute leukemias, obstructing tumors, spinal cord compression — taking one to two weeks to arrange a proper opinion does not compromise treatment. Ask your oncologist directly whether your situation is time-critical. If it is, act accordingly.
Bring someone to appointments. You will not retain everything. A second listener and written notes matter.
Ask what the treatment goal is. Cure, control, or comfort are different objectives with different trade-offs. Understanding which one your team is pursuing changes how you weigh side effects against benefit.
Frequently Asked Questions
Is the number-one ranked hospital the best choice for everyone? No. Rankings aggregate performance across all cancers. Match the center to your specific diagnosis, and weigh travel, insurance, and timing — none of which rankings measure.
How much do rankings actually change year to year? Substantially. There were 51 changes in the U.S. News cancer list between the 2025-26 and 2026-27 editions, including nine hospitals dropping off entirely. Treat rankings as a shortlist tool.
Why do U.S. News and Newsweek disagree? Different methods. U.S. News weights measured clinical outcomes from American claims data heavily. Newsweek’s oncology score is 85% peer reputation from a global physician survey. Both are legitimate; they answer different questions.
Should I travel internationally for cancer treatment? It depends on where you live and what you need. For patients in countries without strong local oncology infrastructure, traveling to an established center can be reasonable. For patients already near an NCI-designated center, the coordination risks usually outweigh the benefits. Discuss it with your treating physician before making arrangements.
What does NCI designation mean for me practically? Broader clinical trial access, subspecialty expertise, and — per a 2015 study — better outcomes at Comprehensive Cancer Centers than at non-designated centers. The current list is published at cancer.gov.
Can I get treated locally but managed by a major center? Often, yes. Many academic centers will develop a treatment plan and coordinate with a local oncologist who administers care near your home. Ask about this explicitly — it is one of the most underused options available and can spare months of travel.
Conclusion
MD Anderson and Memorial Sloan Kettering sit at the top of both major rankings and have for years. If you have a rare or complex cancer and can reach either, both are reasonable destinations.
But for most patients the better process looks like this: find the NCI-designated centers within reach, check whether they are in your insurance network, ask about volume in your specific cancer and trial availability, get a second opinion including pathology review, and confirm your case will go before a multidisciplinary tumor board.
That process will serve you better than any ranked list — including this one.